These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7651889)

  • 41. Vasopressin receptors influencing the secretion of ACTH by the rat adenohypophysis.
    Buckingham JC
    J Endocrinol; 1987 Jun; 113(3):389-96. PubMed ID: 3040881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stimulation of adrenocorticotropin/beta-endorphin release by synthetic ovine corticotropin-releasing factor in vitro. Enhancement by various vasopressin analogs.
    Knepel W; Homolka L; Vlaskovska M; Nutto D
    Neuroendocrinology; 1984 May; 38(5):344-50. PubMed ID: 6328345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of conformationally constrained amino acids replacing positions 2 and 3 of arginine vasopressin (AVP) and its analogues on their pharmacological properties.
    Sobolewski D; Prahl A; Derdowska I; Kwiatkowska A; Slaninová J; Lammek B
    Protein Pept Lett; 2007; 14(3):213-7. PubMed ID: 17346223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.
    Grzonka Z; Kasprzykowski F; Kojro E; Darlak K; Melin P; Fahrenholz F; Crause P; Boer R
    J Med Chem; 1986 Jan; 29(1):96-9. PubMed ID: 2416923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.
    Howl J; Prochazka Z; Wheatley M; Slaninová J
    Br J Pharmacol; 1999 Oct; 128(3):647-52. PubMed ID: 10516644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blockade of alpha 2-adrenoceptors stimulates basal and stress-induced adrenocorticotropin secretion in the developing rat through a central mechanism independent from corticotropin-releasing factor and arginine vasopressin.
    Grino M; Paulmyer-Lacroix O; Faudon M; Renard M; Anglade G
    Endocrinology; 1994 Dec; 135(6):2549-57. PubMed ID: 7988443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gonadotrophin-releasing activity of neurohypophysial hormones: II. The pituitary oxytocin receptor mediating gonadotrophin release differs from that of corticotrophs.
    Evans JJ; Catt KJ
    J Endocrinol; 1989 Jul; 122(1):107-16. PubMed ID: 2475564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potentiation of receptor-mediated cAMP production: role in the cross-talk between vasopressin V1a and V2 receptor transduction pathways.
    Klingler C; Ancellin N; Barrault MB; Morel A; Corman B
    Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):1023-8. PubMed ID: 9480925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.
    Ala Y; Morin D; Mahé E; Cotte N; Mouillac B; Jard S; Barberis C; Tribollet E; Dreifuss JJ; Sawyer WH; Wo NC; Chan WY; Kolodziejczyk AS; Cheng LL; Manning M
    Eur J Pharmacol; 1997 Jul; 331(2-3):285-93. PubMed ID: 9274991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Theoretical conformational analysis of six arginine vasopressin analogs with the L-naphthylalanine in position 3.
    Slusarz R; Kaźmierkiewicz R; Lammek B
    J Pept Res; 2000 Dec; 56(6):352-9. PubMed ID: 11152294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The vasopressin-induced excitation of hypoglossal and facial motoneurons in young rats is mediated by V1a but not V1b receptors, and is independent of intracellular calcium signalling.
    Reymond-Marron I; Tribollet E; Raggenbass M
    Eur J Neurosci; 2006 Sep; 24(6):1565-74. PubMed ID: 17004920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis of 8-D-arginine vasopressin analogues, modified in position 1 as antagonists of the vasopressor response to the parent hormone.
    Lammek B; Derdowska I; Melin P
    Pol J Pharmacol Pharm; 1988; 40(4):423-8. PubMed ID: 3222181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
    J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pituitary receptors for corticotropin-releasing factor: no effect of vasopressin on binding or activation of adenylate cyclase.
    Holmes MC; Antoni FA; Szentendrei T
    Neuroendocrinology; 1984 Aug; 39(2):162-9. PubMed ID: 6089019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line.
    Nambi P; Whitman M; Gessner G; Aiyar N; Crooke ST
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8492-5. PubMed ID: 2430290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stability of the vasopressin V2 receptor-adenylyl cyclase system in rat kidney.
    Shen T; Laycock J; Suzuki Y; Defer N; Hanoune J
    Eur J Pharmacol; 1998 Jan; 341(1):87-94. PubMed ID: 9489860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities.
    Morin D; Cotte N; Balestre MN; Mouillac B; Manning M; Breton C; Barberis C
    FEBS Lett; 1998 Dec; 441(3):470-5. PubMed ID: 9891993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular vasopressin receptors mediate inhibition of beta adrenergic receptor-induced cyclic AMP accumulation.
    Nambi P; Whitman M; Stassen FL; Crooke ST
    J Pharmacol Exp Ther; 1986 Apr; 237(1):143-6. PubMed ID: 3007735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of arginine-8-vasopressin and 1-deamino-8-D-arginine-vasopressin on ACTH secretion in rats.
    László FA; Janáky T; Julesz J; Kárteszi M; Makara GB; Stark E
    Endocrinol Exp; 1983 Jun; 17(2):133-6. PubMed ID: 6309504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo and in vitro effects of arginine-vasopressin receptor antagonists on the hypothalamic-pituitary-adrenal axis in the rat.
    Bernardini R; Chiarenza A; Kamilaris TC; Renaud N; Lempereur L; Demitrack M; Gold PW; Chrousos GP
    Neuroendocrinology; 1994 Nov; 60(5):503-8. PubMed ID: 7845540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.